CC
XENE icon

Commodore Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Commodore Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-825,000
Closed -$48M – 41
2026
Q1 		$48M Sell
825,000
-975,000
-54% -$44.9M 2.78% 15
2025
Q4 		$80.7M Sell
1,800,000
-900,000
-33% -$37.8M 5.37% 4
2025
Q3 		$108M Sell
2,700,000
-325,000
-11% -$11.4M 5.29% 3
2025
Q2 		$94.7M Buy
3,025,000
+700,000
+30% +$22.8M 6.68% 3
2025
Q1 		$78M Sell
2,325,000
-415,000
-15% -$15.8M 5.75% 5
2024
Q4 		$107M Buy
2,740,000
+40,000
+1% +$1.65M 7.87% 4
2024
Q3 		$106M Sell
2,700,000
-54,266
-2% -$2.19M 6.64% 3
2024
Q2 		$107M Buy
2,754,266
+586,473
+27% +$23.4M 7.33% 3
2024
Q1 		$93.3M Hold
2,167,793
– – 6.24% 4
2023
Q4 		$99.8M Buy
2,167,793
+322,793
+17% +$11.4M 8.72% 2
2023
Q3 		$63M Hold
1,845,000
– – 7.37% 3
2023
Q2 		$71M Hold
1,845,000
– – 7.98% 4
2023
Q1 		$66M Buy
1,845,000
+185,889
+11% +$6.87M 10.05% 1
2022
Q4 		$65.4M Buy
1,659,111
+64,179
+4% +$2.34M 9.86% 1
2022
Q3 		$57.6M Hold
1,594,932
– – 9.26% 2
2022
Q2 		$48.5M Buy
1,594,932
+392,319
+33% +$11.9M 10.26% 2
2022
Q1 		$36.8M Buy
1,202,613
+112,487
+10% +$3.37M 8.21% 5
2021
Q4 		$34.1M Buy
1,090,126
+510,694
+88% +$15.3M 7.89% 4
2021
Q3 		$8.85M Buy
579,432
+253,096
+78% +$4.4M 2.33% 17
2021
Q2 		$6.08M Buy
326,336
+24,944
+8% +$460K 2.12% 20
2021
Q1 		$5.39M Sell
301,392
-165,976
-36% -$2.81M 2.15% 21
2020
Q4 		$7.19M Buy
+467,368
New +$5.47M 3.91% 12

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Commodore Capital's XENE Position: Q2 2026 in Review

Commodore Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 825,000 shares — an estimated $48M sold.

Commodore Capital first reported a position in XENE in Q4 2020 and held it in 22 quarters. The position peaked at $108M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Commodore Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Commodore Capital sold 825,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $48M.
  • Commodore Capital first reported a position in Xenon Pharmaceuticals in Q4 2020 and held it in 22 quarters.
  • Commodore Capital's Xenon Pharmaceuticals position peaked at $108M in Q3 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.